Get the Stockscreener App
27.65
1.69%
0.46
After Hours:
27.50
-0.15
-0.54%
Greenwich Lifesciences Inc stock is traded at $27.65, with a volume of 73,952.
It is up +1.69% in the last 24 hours and up +10.87% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$27.19
Open:
$27.22
24h Volume:
73,952
Relative Volume:
0.50
Market Cap:
$383.08M
Revenue:
-
Net Income/Loss:
$-19.48M
P/E Ratio:
-18.89
EPS:
-1.4641
Net Cash Flow:
$-8.59M
1W Performance:
+1.62%
1M Performance:
+10.87%
6M Performance:
+239.26%
1Y Performance:
+182.14%
1-Day Range:
$27.22
$28.78
1-Week Range:
$25.80
$28.78
52-Week Range:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
27.65 | 376.70M | 0 | -19.48M | -8.59M | -1.4641 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
(GLSI) Volatility Zones as Tactical Triggers - Stock Traders Daily
Greenwich LifeSciences receives Nasdaq noncompliance notice By Investing.com - Investing.com Nigeria
Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-Q filing - MSN
Greenwich LifeSciences: Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - Moomoo
Greenwich LifeSciences receives Nasdaq noncompliance notice - Investing.com
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - Weekly Voice
Nasdaq flags breast cancer drug developer over late SEC filing - Stock Titan
Greenwich Lifesciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Price-Driven Insight from (GLSI) for Rule-Based Strategy - Stock Traders Daily
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Greenwich LifeSciences (NASDAQ:GLSI) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Greenwich LifeSciences (GLSI) shares fall 3% despite tiny EPS beat; investors demand clinical progress updates. - newser.com
(GLSI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Greenwich LifeSciences delays annual report filing - Investing.com UK
Greenwich LifeSciences delays annual report filing By Investing.com - Investing.com Australia
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing - The Manila Times
Europe trial enrollment jump leaves Greenwich finalizing 10-K figures - Stock Titan
GLSI Stock Price, Quote & Chart | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Why did Greenwich LifeSciences stock soar pre-market today? - MSN
Should investors enter Greenwich LifeSciences (GLSI) stock today | Greenwich LifeSciences posts tiny EPS beat, no revenue reportedTrending Social Stocks - newser.com
Why is GLSI stock rising today? - MSN
Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-K filing - MSN
Greenwich LifeSciences (NASDAQ:GLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Greenwich LifeSciences (GLSI) and Actinogen Medical (OtherATGGF) - The Globe and Mail
HC Wainwright Has Bearish Estimate for GLSI FY2026 Earnings - MarketBeat
ASCO 2026 to feature Greenwich LifeSciences research poster - Traders Union
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 - ChartMill
GLSI (Greenwich LifeSciences Inc.) reports narrow Q3 2025 EPS beat, shares climb 2.36 percent on positive investor sentiment.Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Breast cancer immunotherapy study lands ASCO 2026 poster slot - Stock Titan
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - ChartMill
H.C. Wainwright Maintains Greenwich LifeSciences(GLSI.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Nasdaq flags Greenwich LifeSciences over delayed 2025 annual report - Stock Titan
(GLSI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Why Did GLSI Stock Rise Pre-Market Today? - Stocktwits
Why did GLSI stock rise pre-market today? - MSN
Greenwich LifeSciences shares rise on breast cancer vaccine trial data By Investing.com - Investing.com Canada
Greenwich LifeSciences unveils preliminary FLAMINGO-01 open label data at AACR Meeting - Traders Union
Breast cancer immunotherapy shows 4x immune response in Phase III data - Stock Titan
Is Greenwich LifeSciences (GLSI) stock still attractive (Bullish Sentiment) 2026-04-18Stock Idea Sharing Hub - Xã Thanh Hà
Greenwich LifeSciences (GLSI) Stock Rule Based Trade (Investors Pile In) 2026-04-16Shared Buy Zones - Xã Châu Thành
Greenwich LifeSciences (GLSI) Stock Rights Issue (At Lows) 2026-04-15Viral Trades - Cổng thông tin điện tử tỉnh Lào Cai
Greenwich Lifesciences Provides Clinical Trial and Pipeline Update - National Today
Greenwich LifeSciences reports Q1 cash balance of $10.5 million By Investing.com - Investing.com Australia
Strategic financing update revealed by Greenwich LifeSciences - Traders Union
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Greenwich Lifesciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):